{
    "clinical_study": {
        "@rank": "110777", 
        "arm_group": [
            {
                "arm_group_label": "320U /0.5ml in children (from 2 to 5 years old)", 
                "arm_group_type": "Experimental", 
                "description": "inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28"
            }, 
            {
                "arm_group_label": "0/0.5ml placebo in children (from 2 to 5 years old)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28"
            }
        ], 
        "brief_summary": {
            "textblock": "Recently, an inactivated vaccine (vero cell) against EV71 has been investigated in Phase 1\n      and Phase 2 clinical trials. Data from these trials showed that the EV71 vaccine has good\n      safety profile and was immunogenic. 320 U alum-adjuvant vaccine has been chosen as the\n      candidate vaccine for the phase 3 clinical trial.\n\n      This clinical trial is a supplementary phase 2 trial, which is designed to study the gene\n      expression patterns induced by EV71 vaccine in Chinese healthy children aged from 2 to 5\n      years old use a systems biology approach combined with microarray analysis\uff0cRT-PCR and\n      neutralizing antibody testing for PBMC and serum collected form the studied children\n      population, to predict immunogenicity, and explore mechanistic insights about the EV71\n      vaccine."
        }, 
        "brief_title": "Systems Biology of Vaccination for EV71 Vaccine in Humans", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Systems Biology", 
            "Early Gene", 
            "EV71 Vaccine"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects aged from 2 to 5 years old as established by medical history and\n             clinical examination\n\n          -  The pre-vaccination neutralizing antibody against EV71 <1:8 which is determined by\n             ELISA\n\n          -  The subjects' guardians are able to understand and sign the informed consent\n\n          -  Had never received the vaccine against EV71\n\n          -  Subjects who can and will comply with the requirements of the protocol\n\n          -  Subjects with temperature \uff1c37.1\u00b0C on axillary setting\n\n        Exclusion Criteria:\n\n          -  Subject who has a medical history of HFMD\n\n          -  <= 37 weeks gestation\n\n          -  Subjects with a birth weight <2.5 kg\n\n          -  Subject that has a medical history of any of the following: allergic history, or\n             allergic to any ingredient of vaccine\n\n          -  Family history of seizures or progressive neurological disease\n\n          -  Family history of congenital or hereditary immunodeficiency\n\n          -  Severe malnutrition or dysgenopathy\n\n          -  Major congenital defects or serious chronic illness, including perinatal brain damage\n\n          -  Autoimmune disease\n\n          -  Bleeding disorder diagnosed by a doctor or significant bruising or bleeding\n             difficulties with IM injections or blood draws\n\n          -  Any acute infections in last 7 days\n\n          -  Any prior administration of immunodepressant or corticosteroids in last 6month\n\n          -  Any prior administration of blood products in last 3 month\n\n          -  Any prior administration of other research medicines in last 1month\n\n          -  Any prior administration of attenuated live vaccine in last 28 days\n\n          -  Any prior administration of inactivated vaccines in last 14 days, such as\n             pneumococcal vaccine\n\n          -  Under the anti - TB prevention or therapy\n\n          -  Any condition that in the opinion of the investigator, may interfere with the\n             evaluation of study objectives"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "5 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679665", 
            "org_study_id": "JSVCT012"
        }, 
        "intervention": [
            {
                "arm_group_label": "320U /0.5ml in children (from 2 to 5 years old)", 
                "description": "inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval", 
                "intervention_name": "320U /0.5ml", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "0/0.5ml placebo in children (from 2 to 5 years old)", 
                "description": "0/0.5ml placebo, two doses, 4 weeks interval", 
                "intervention_name": "0/0.5ml placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210009"
                }, 
                "name": "Jiangsu Provincial Center for Diseases Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Systems Biology of Vaccination for EV71 Vaccine in Chinese Healthy Children Aged From 2 to 5 Years Old", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 3 in children aged 2-5 years", 
                "measure": "Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine", 
                "safety_issue": "No", 
                "time_frame": "Frame: 3 days after first dose"
            }, 
            {
                "description": "Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 7 in children aged 2-5 years", 
                "measure": "Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine", 
                "safety_issue": "No", 
                "time_frame": "7 days after first dose"
            }, 
            {
                "description": "Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 28 in children aged 2-5 years", 
                "measure": "Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine", 
                "safety_issue": "No", 
                "time_frame": "28 days after first dose"
            }, 
            {
                "description": "Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 56 in children aged 2-5 years", 
                "measure": "Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine", 
                "safety_issue": "No", 
                "time_frame": "28 days after second dose"
            }, 
            {
                "description": "Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at month 6 in children aged 2-5 years", 
                "measure": "Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine", 
                "safety_issue": "No", 
                "time_frame": "6 months after first dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679665"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "GMT, seroconversion rate of anti-EV71 antibodies in serum 28 days after first vaccination", 
                "measure": "GMT, seroconversion rate of anti-EV71 antibodies in serum after first vaccination", 
                "safety_issue": "No", 
                "time_frame": "28 days after the first vaccination"
            }, 
            {
                "description": "GMT, seroconversion rate of anti-EV71 antibodies in serum 28 days after second vaccination", 
                "measure": "GMT, seroconversion rate of anti-EV71 antibodies in serum after second vaccination", 
                "safety_issue": "No", 
                "time_frame": "28 days after second vaccination"
            }, 
            {
                "description": "Frequency of systemic and local adverse reactions within 28 days after the first dose of EV71 vaccine in healthy children aged 2-5 years", 
                "measure": "the safety of EV71 vaccine in healthy children aged 2-5 years", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after the first dose"
            }, 
            {
                "description": "Frequency of systemic and local adverse reactions within 28 days after the second dose of EV71 vaccine in healthy children aged 2-5 years", 
                "measure": "the safety of EV71 vaccine in healthy children aged 2-5 years", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after the second dose"
            }
        ], 
        "source": "Jiangsu Province Centers for Disease Control and Prevention", 
        "sponsors": {
            "collaborator": {
                "agency": "Bejing Vigoo Biological Co., LTD", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu Province Centers for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}